Summit Therapeutics Partners with AstraZeneca and Daiichi Sankyo on Ivonescimab Trial for Solid Tumors
Event summary
- Summit Therapeutics will collaborate with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab in combination with Datroway in multiple solid tumor settings, starting with a Phase III trial in first-line triple-negative breast cancer (TNBC).
- Ivonescimab is a novel PD-1/VEGF bispecific antibody, while Datroway is a TROP2-directed antibody drug conjugate (ADC).
- Each company will contribute their respective therapies and share trial costs, retaining commercial rights to their medicines.
- Over 5,000 patients have been treated with ivonescimab in clinical studies globally, with additional commercial use in China.
The big picture
This collaboration underscores the growing trend of strategic partnerships in oncology to accelerate the development of next-generation immunotherapies. The combination of ivonescimab’s unique bispecific design with Datroway’s targeted ADC approach could set a new benchmark for treating solid tumors, particularly in breast and lung cancer. The deal highlights the increasing focus on innovative combinations to drive deeper, more durable responses in cancer treatment.
What we're watching
- Clinical Trial Success
- Whether the Phase III trial in TNBC will demonstrate the efficacy of the ivonescimab and Datroway combination, potentially expanding treatment options for aggressive cancers.
- Regulatory Approvals
- The timeline for potential regulatory approvals of ivonescimab in Summit’s license territories, following its initial approval in China.
- Market Competition
- How this collaboration positions Summit Therapeutics against competitors in the rapidly evolving oncology space.